靶向抗血管生成药物联合细胞毒性化疗在肉瘤临床前和临床研究中的应用。

Clinical Sarcoma Research Pub Date : 2016-06-07 eCollection Date: 2016-01-01 DOI:10.1186/s13569-016-0049-z

Kieuhoa T Vo, Katherine K Matthay, Steven G DuBois

{"title":"靶向抗血管生成药物联合细胞毒性化疗在肉瘤临床前和临床研究中的应用。","authors":"Kieuhoa T Vo, Katherine K Matthay, Steven G DuBois","doi":"10.1186/s13569-016-0049-z","DOIUrl":null,"url":null,"abstract":"Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas. However, when used as monotherapy in the clinical setting, these targeted antiangiogenic agents have only provided modest survival benefits in some sarcoma subtypes, and have not been efficacious in others. Preclinical and early clinical data suggest that the addition of conventional chemotherapy to antiangiogenic agents may lead to more effective therapies for patients with these tumors. In the current review, the authors summarize the available evidence and possible mechanisms supporting this approach. ","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"6 ","pages":"9"},"PeriodicalIF":0.0000,"publicationDate":"2016-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-016-0049-z","citationCount":"11","resultStr":"{\"title\":\"Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma.\",\"authors\":\"Kieuhoa T Vo, Katherine K Matthay, Steven G DuBois\",\"doi\":\"10.1186/s13569-016-0049-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas. However, when used as monotherapy in the clinical setting, these targeted antiangiogenic agents have only provided modest survival benefits in some sarcoma subtypes, and have not been efficacious in others. Preclinical and early clinical data suggest that the addition of conventional chemotherapy to antiangiogenic agents may lead to more effective therapies for patients with these tumors. In the current review, the authors summarize the available evidence and possible mechanisms supporting this approach. \",\"PeriodicalId\":10684,\"journal\":{\"name\":\"Clinical Sarcoma Research\",\"volume\":\"6 \",\"pages\":\"9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-06-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/s13569-016-0049-z\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Sarcoma Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s13569-016-0049-z\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2016/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Sarcoma Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13569-016-0049-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 11

摘要

肉瘤是一种异质性间质恶性肿瘤。近年来的研究表明，抑制血管生成途径或破坏已建立的血管系统可以减弱肉瘤的生长。然而，当在临床环境中作为单一疗法使用时，这些靶向抗血管生成药物仅在某些肉瘤亚型中提供适度的生存益处，并且在其他亚型中无效。临床前和早期临床数据表明，在抗血管生成药物的基础上增加常规化疗可能会为这些肿瘤患者带来更有效的治疗方法。在当前的综述中，作者总结了支持这种方法的现有证据和可能的机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma.

Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas. However, when used as monotherapy in the clinical setting, these targeted antiangiogenic agents have only provided modest survival benefits in some sarcoma subtypes, and have not been efficacious in others. Preclinical and early clinical data suggest that the addition of conventional chemotherapy to antiangiogenic agents may lead to more effective therapies for patients with these tumors. In the current review, the authors summarize the available evidence and possible mechanisms supporting this approach.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Sarcoma Research

自引率

0.00%

发文量

期刊介绍： Clinical Sarcoma Research considers for publication articles related to research on sarcomas, including both soft tissue and bone. The journal publishes original articles and review articles on the diagnosis and treatment of sarcomas along with new insights in sarcoma research, which may be of immediate or future interest for diagnosis and treatment. The journal also considers negative results, especially those from studies on new agents, as it is vital for the medical community to learn whether new agents have been proven effective or ineffective within subtypes of sarcomas. The journal also aims to offer a forum for active discussion on topics of major interest for the sarcoma community, which may be related to both research results and methodological topics.